Search Bar & Filters
Found 16 Actively Recruiting clinical trials
Actively Recruiting
Healthy Volunteer
Researchers are evaluating the performance of an artificial intelligence software called Osteo Signal in detecting osteoporosis risk among adults aged 50 years and older. The study compares the accuracy of this AI software using chest x-ray images against the standard method of dual-energy x-ray absorptiometry DXA. This observational study involves reviewing existing medical imaging data rather than direct participant involvement. The study uses previously collected chest x-rays and DXA scans performed within six months of each other, starting from scans taken on or after January 1, 2010. The AI software is assessed for its ability to classify bone status into categories such as osteoporosis and osteopenia, comparing its results to those from the DXA scans. No new treatments or procedures are administered to participants. Participants have already undergone chest x-rays and DXA scans, and their data, including age and sex, are analyzed retrospectively. Researchers measure bone status classification accuracy based on the images, focusing on whether the software correctly identifies osteoporosis and osteopenia. The study does not require active participation and relies on existing data, with the goal of improving screening methods for osteoporosis in adults aged 50 and above.
Actively Recruiting
Researchers are evaluating the medicine BI 1815368 in adults aged 18 and older who have a specific eye condition called centre-involved diabetic macular edema CI-DME, a type of diabetic macular edema. The purpose is to determine if BI 1815368 helps improve vision and to identify the best dose. This randomized, double-masked, placebo-controlled Phase 2 trial is sponsored by Boehringer Ingelheim. The study has two parts. In the first part, participants are randomly assigned to take either BI 1815368 tablets or placebo tablets that look identical but contain no medicine. In the second part, participants are randomly assigned to one of four groups three groups receive different daily doses of BI 1815368, and one group receives placebo. All participants take tablets twice daily for about 11 months. Participants stay in the study for about one year, visiting the study site at least 16 times. Those taking metformin have three extra visits. At each visit, doctors check vision, record any health issues, and take detailed pictures of the eye using advanced imaging. Researchers compare vision changes over time between groups to assess the medicines effect. Safety and tolerability are also monitored throughout the study.
Actively Recruiting
This research aims to compare the effects of oral anticoagulation versus no anticoagulation in patients aged 55 and older who have had recent episodes of transient atrial fibrillation triggered by stress and have additional factors that increase their risk of stroke. The study is a multinational, investigator-initiated, prospective, randomized, open-label trial evaluating the impact of non-vitamin K oral anticoagulants NOACs on preventing stroke and other serious cardiovascular events. Participants will be randomly assigned to either receive one of several NOACs, such as edoxaban, apixaban, dabigatran, or rivaroxaban, prescribed by their physician for the duration of the follow-up, or to a control group that will not receive anticoagulants unless medically indicated during the study. The choice of specific NOAC and dose adjustments are determined by the prescribing doctor. The study excludes patients with certain conditions like chronic atrial fibrillation, severe kidney or liver disease, recent cardiac surgery, or bleeding risks. During the study, participants will be monitored for up to 24 months to assess the occurrence of non-hemorrhagic stroke, systemic embolism, vascular mortality, myocardial infarction, peripheral arterial thrombosis, amputation, and venous thromboembolism. Regular follow-up will include evaluation of these outcomes to measure the effectiveness and safety of anticoagulation compared to no anticoagulation. Participants will provide informed consent and remain under medical supervision throughout the trial.
Actively Recruiting
Researchers are evaluating whether skipping additional axillary treatment for patients with early-stage breast cancer who had cancer in their lymph nodes before chemotherapy but show no remaining cancer in those nodes after treatment is as effective as the standard approach. This study focuses on disease-free survival and reducing the risk of lymphoedema five years after treatment. It is a randomized, open, multicenter trial including patients with specific breast cancer stages and confirmed nodal metastases. Participants will all receive standard therapies including HER2-targeted treatment, endocrine therapy, and radiotherapy to the breast or chest wall if needed. They will be randomly assigned to one of two groups one group will not get further axillary treatment such as lymph node removal or radiotherapy, while the other group will receive these axillary treatments according to local guidelines. Follow-up visits will occur annually for at least five years. During the study, participants will undergo assessments to monitor disease-free survival and self-reported lymphoedema using specific questionnaires. Additional evaluations include arm function, quality of life, recurrence rates, survival, and cost-effectiveness analyses. The total study duration is planned for 120 months, including setup, recruitment, follow-up, analysis, and reporting.
Actively Recruiting
Benign prostatic hyperplasia BPH is a common condition affecting men, especially with increasing age, and is one of the most performed surgical procedures in urology. This study establishes an ongoing international registry under uCARE to collect and analyze demographic data and clinical outcomes for men undergoing medical or surgical treatments for BPH. The registry aims to provide real-world data on treatment patterns and outcomes worldwide, helping to identify practice trends and preferences. Participants included are men aged 18 years and older diagnosed with BPH and lower urinary tract symptoms LUTS who have been prescribed either medications or surgical interventions for BPH. The registry records baseline demographic and clinical data, peri-operative details, and follow-up information using validated tools such as the International Prostate Symptom Score IPSS, Sexual Health Inventory for Men SHIM, and Male Sexual Health Questionnaire for Ejaculatory Dysfunction MSHQ-EjD, as well as clinical measures like quality of life, maximum flow rate, post-void residual, prostate-specific antigen, and testosterone levels. Complications including bleeding, urinary tract infections, incontinence, and sexual dysfunction are also tracked. Participants medical records are securely entered into the registry with data validation and periodic audits to ensure accuracy. Data collection continues for three years with no fixed endpoint for follow-up, allowing for ongoing research and publication of findings. Access to registry data is protected and restricted to site-specific users, ensuring patient privacy and data security. The registry aims to support future studies and improve understanding of BPH treatment outcomes globally.
Actively Recruiting
Researchers are conducting a multi-centre observational study to better understand giant cell arteritis GCA and polymyalgia rheumatica PMR, conditions mainly affecting people over 50 years old. The study aims to identify genetic factors that influence susceptibility to these diseases to provide new insights into how they develop. It includes both retrospective participants with confirmed diagnoses and prospective participants suspected of having these conditions, with some patients also enrolled in a registry monitoring tocilizumab treatment for relapsing or refractory GCA. The study collects detailed clinical, imaging, and molecular data, including genetic and proteomic analyses, from participants to characterize disease subtypes and impacts. Researchers also assess quality of life through patient-reported outcomes and track long-term prognosis by linking to health records. The study explores environmental factors and co-existing conditions to improve diagnosis, prognosis, and monitoring of disease activity, especially for patients receiving synthetic or biological disease-modifying anti-rheumatic drugs. Participants provide information during baseline assessments, including blood and urine samples for analysis, and complete questionnaires about their symptoms and quality of life. Follow-up occurs through health record review over an average of one year to evaluate diagnosis and disease outcomes. The primary measure is genetic susceptibility, with secondary outcomes focusing on disease characteristics, life impact, diagnosis, and disease activity. The study is sponsored by the University of Leeds and started in 2005, continuing through 2028.
Actively Recruiting
Researchers are evaluating the safety and performance of remote monitoring functions in ALIZEA, BOREA, and CELEA pacemakers for patients with bradycardia. This observational clinical investigation focuses on the devices Right Atrial Autothreshold RAAT, Right Ventricular Autothreshold RVAT, and remote alert features. The study aims to document these functions over time to better understand their reliability and safety. Participants will be included soon after pacemaker implantation and followed for 48 months. Follow-up visits occur both on-site and remotely at 1 to 3 months, 6 months, 12 months, 24 months, and 48 months after inclusion. During these visits, the remote monitoring functions and the pacing systems performance will be measured, and safety will be continuously monitored throughout the study. Throughout the study, researchers will assess cardiac pacing thresholds, technical remote alerts, and the usability of the pacemaker and remote monitoring systems. Evaluations include Right Atrial and Right Ventricular pacing thresholds at multiple timepoints up to 48 months. Participants will undergo scheduled check-ins involving measurements, monitoring, and safety assessments, with the total study duration lasting four years after enrollment.
Actively Recruiting
Researchers are evaluating the outcomes of different coronary artery bypass grafting techniques in women with heart disease. The trial compares multiple arterial grafting MAG to single arterial grafting SAG to see if using multiple arterial grafts improves major heart and brain-related events and quality of life. This international randomized clinical trial includes 2,300 women to assess differences in survival, stroke, heart attacks, repeat surgeries, and hospital readmissions, as well as physical and mental health. Participants will be randomly assigned to one of two groups. One group receives a single arterial graft using the left internal thoracic artery plus additional venous grafts. The other group receives multiple arterial grafts, including the left internal thoracic artery and at least one other arterial graft such as the right internal thoracic artery or radial artery, with possible additional arterial grafts. The study uses the infrastructure of an existing trial and follows patients for at least 2.5 years after surgery. During the study, researchers collect data on major adverse cardiac and cerebrovascular events, along with quality of life measured by general and disease-specific questionnaires. Physical and mental health symptoms are also assessed. Follow-up includes tracking deaths, strokes, heart attacks, repeat procedures, and hospital stays. The trial aims to provide detailed information on outcomes and quality of life in women undergoing coronary bypass surgery over a long-term period.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of MTX-474, a monoclonal antibody, in adults with diffuse cutaneous systemic sclerosis dcSSc, a condition causing skin thickening and organ involvement. This Phase 2 randomized, double-blind, placebo-controlled trial aims to compare MTX-474 with a placebo to better understand its impact on the skin symptoms of dcSSc. Participants will be randomly assigned to receive either MTX-474 or a placebo via intravenous infusion every 4 weeks, from the start of the study through Week 20. The study allows some participants to continue approved dcSSc treatments under specific conditions. Treatment visits continue through Week 24, followed by a safety follow-up visit at Week 28. Throughout the study, participants will have regular skin assessments using the Modified Rodnan Skin Score mRSS, lung function tests including spirometry and DLCO, and imaging with high-resolution CT scans at screening and Week 24. Skin biopsies will be taken at baseline and Week 12, and blood samples will be collected at screening, baseline, and every 4 weeks until Week 28 to monitor safety, drug levels, and biomarkers. The main outcome measured is the change in skin thickness from the start to Week 24, along with safety and tolerability assessments extending through Week 28.
Actively Recruiting
Researchers are evaluating the use of two types of MRI scans and two biopsy methods to improve prostate cancer diagnosis. The study focuses on whether biparametric MRI bpMRI, which is shorter and does not use contrast dye, can be an alternative to the longer multiparametric MRI mpMRI that uses gadolinium contrast. It also compares image-fusion targeted biopsy, which overlays MRI and ultrasound images during biopsy, with visual-registration targeted biopsy, where biopsy locations are chosen by looking at MRI images separately. Participants first receive either the mpMRI or bpMRI scan. If the MRI suggests cancer, the clinical team decides if a biopsy is needed. Those advised for biopsy undergo either a visual-registration targeted biopsy or an image-fusion targeted biopsy. Both biopsy methods include taking systematic tissue samples to check for cancer. The study does not blind participants or doctors to the MRI or biopsy type used. During the study, participants undergo MRI scans and possibly biopsies based on clinical advice. Researchers collect data on how many clinically significant prostate cancers are detected within 12 weeks of enrollment. They also assess any adverse events related to MRI and biopsy procedures, patient-reported outcomes, and accuracy of cancer detection using different scoring systems. The total duration for outcome assessment is up to 12 weeks after joining the study.
1-10 of 16
1